TP53 and cancer: Due to the identification of reliable molecular biomarkers, EC is no longer grouped in estrogen-dependent (Type I) and estrogen-independent (Type II) types [4], but is now classified according to the ProMisE-algorithm: this includes Mismatch repair (MMR-)-deficiency, Polymerase ε (POLE) mutated, p53 wildtype and p53 aberrant cancers [5,6].